The effect of etanercept on vascular endothelial growth factor production by cutaneous mesenchymal stem cells from patients with psoriasis.
OBJECTIVE
To evaluate prospectively the effect of etanercept (a tumour necrosis factor [TNF]-α inhibitor) on vascular endothelial growth factor (VEGF) production by mesenchymal stem cells (MSC) from patients with psoriasis.


METHODS
MSCs from lesional and perilesional skin were isolated, cultured and characterized. VEGF production was evaluated at baseline and after 12 weeks' etanercept treatment.


RESULTS
Etanercept treatment resulted in significant reductions in VEGF production compared with baseline in both lesional MSCs (256.42 ± 3.07 pg/ml per 106cells at baseline vs 27.66 ± 2.03 pg/ml per 106cells after treatment) and perilesional MSCs (235.03 ± 2.52 pg/ml per 106cells vs 41.65 ± 4.72 pg/ml per 106cells).


CONCLUSIONS
Etanercept reduces the production of VEGF in MSCs, which may modulate angiogenesis and contributes towards preventing the start of the "psoriatic march".
Department of Clinical and Molecular Sciences - Dermatological Clinic, Polytechnic Marche University, Ancona, Italy.
Anna
A
Campanati
Department of Clinical and Molecular Sciences - Histology, Polytechnic Marche University, Ancona, Italy.
Monia
M
Orciani
Department of Clinical and Molecular Sciences - Dermatological Clinic, Polytechnic Marche University, Ancona, Italy giulia.ganzetti@alice.it.
Giulia
G
Ganzetti
Department of Clinical and Molecular Sciences - Dermatological Clinic, Polytechnic Marche University, Ancona, Italy.
Veronica
V
Consales
Department of Clinical and Molecular Sciences - Histology, Polytechnic Marche University, Ancona, Italy.
Roberto
R
Di Primio
Department of Clinical and Molecular Sciences - Histology, Polytechnic Marche University, Ancona, Italy.
Annamaria
A
Offidani
Angiogenesis; cutaneous mesenchymal stem cells; etanercept; psoriasis; vascular endothelial growth factor
Int J Exp Pathol. 2009 Jun;90(3):232-48
19563608
Biologics. 2014 Apr 17;8:169-82
24790410
Skin Pharmacol Physiol. 2010;23(3):124-32
20051713
J Crohns Colitis. 2012 Oct;6(9):962-3
22727660
Int J Dermatol. 2008 Jul;47(7):732-6
18613885
Exp Dermatol. 2011 Apr;20(4):303-7
21410760
Expert Opin Biol Ther. 2013 Dec;13(12):1673-82
24107126
Am J Clin Dermatol. 2010;11 Suppl 1:46-8
20586509
J Gastroenterol. 2013 Jul;48(7):839-46
23065020
Br J Dermatol. 2012 Jul;167(1):68-76
22356229
J Am Acad Dermatol. 2004 Oct;51(4):563-9
15389191
Eur J Dermatol. 2002 Sep-Oct;12(5):496-8
12370145
Arch Dermatol Res. 2010 Jul;302(5):367-74
20035428
Free Radic Biol Med. 2010 Sep 1;49(5):830-8
20541604
Arch Dermatol Res. 2014 Dec;306(10):915-20
25160906
Int J Immunopathol Pharmacol. 2009 Apr-Jun;22(2):371-7
19505391
Br J Dermatol. 2011 Sep;165(3):585-92
21623755
Br J Dermatol. 2007 May;156(5):945-50
17388922